tetano
Editor, Senior Moderator
Vaccine. 2014 Jun 17. pii: S0264-410X(14)00799-3. doi: 10.1016/j.vaccine.2014.06.010. [Epub ahead of print]
Factors associated with humoral immune response to pandemic A/H1N1(v) 2009 influenza vaccine in cystic fibrosis.
Launay O1, Boelle PY2, Krivine A3, Grenet D4, Boussaud V5, R?mus N6, Corvol H7, Chedevergne F8, Hubert D9, Sermet-Gaudelus I10; Inserm MUCOFLU group.
Author information
Abstract
Influenza vaccination is recommended in cystic fibrosis patients. The objective of this study was to assess the immunogenicity of vaccination against 2009 pandemic A/H1N1 influenza and to study the factors associated with the immune response in patients with cystic fibrosis. 122 patients with cystic fibrosis were enrolled in a prospective study and received 1 dose of 2009/H1N1v adjuvanted vaccine, or for children <2 years and lung-transplanted patients, two doses of non-adjuvanted 2009/H1N1v vaccine administered 21 days apart. Hemagglutination inhibition antibodies were assessed before and 21 days after vaccination and at least 6 months after vaccination. After vaccination, 85% of the patients had an influenza antibody titer ≥1:40 and 69% seroconverted. 13% of the transplanted patients seroconverted compared with 72% of the non-transplanted patients. In this latter group, non-adjuvanted vaccine and low body mass index were independently associated with lower response to vaccination. 86% of the non-transplanted patients with normal BMI and receiving adjuvanted vaccine seroconverted. Persistence of seroprotection 10 months after vaccination was found in 50% of the patients. In patients with cystic fibrosis, malnutrition and receipt of non-adjuvanted vaccine were associated with lower immune response to pandemic influenza vaccination. Our data also suggest a potential defect in the immune response to influenza vaccination of patients with cystic fibrosis and raise the question of whether a different immunization strategy is needed.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Adjuvanted vaccine; Cystic fibrosis; Influenza; Malnutrition; Pandemic; Vaccine
PMID:
24950362
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24950362
Factors associated with humoral immune response to pandemic A/H1N1(v) 2009 influenza vaccine in cystic fibrosis.
Launay O1, Boelle PY2, Krivine A3, Grenet D4, Boussaud V5, R?mus N6, Corvol H7, Chedevergne F8, Hubert D9, Sermet-Gaudelus I10; Inserm MUCOFLU group.
Author information
Abstract
Influenza vaccination is recommended in cystic fibrosis patients. The objective of this study was to assess the immunogenicity of vaccination against 2009 pandemic A/H1N1 influenza and to study the factors associated with the immune response in patients with cystic fibrosis. 122 patients with cystic fibrosis were enrolled in a prospective study and received 1 dose of 2009/H1N1v adjuvanted vaccine, or for children <2 years and lung-transplanted patients, two doses of non-adjuvanted 2009/H1N1v vaccine administered 21 days apart. Hemagglutination inhibition antibodies were assessed before and 21 days after vaccination and at least 6 months after vaccination. After vaccination, 85% of the patients had an influenza antibody titer ≥1:40 and 69% seroconverted. 13% of the transplanted patients seroconverted compared with 72% of the non-transplanted patients. In this latter group, non-adjuvanted vaccine and low body mass index were independently associated with lower response to vaccination. 86% of the non-transplanted patients with normal BMI and receiving adjuvanted vaccine seroconverted. Persistence of seroprotection 10 months after vaccination was found in 50% of the patients. In patients with cystic fibrosis, malnutrition and receipt of non-adjuvanted vaccine were associated with lower immune response to pandemic influenza vaccination. Our data also suggest a potential defect in the immune response to influenza vaccination of patients with cystic fibrosis and raise the question of whether a different immunization strategy is needed.
Copyright ? 2014. Published by Elsevier Ltd.
KEYWORDS:
Adjuvanted vaccine; Cystic fibrosis; Influenza; Malnutrition; Pandemic; Vaccine
PMID:
24950362
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24950362